{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:49:04Z","timestamp":1776048544434,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>SARS-CoV-2 infection continues to impact global health, particularly among high-risk vulnerable individuals. With the loss of federal funding for SARS-CoV-2 management, hospitals will need to budget appropriately for antivirals like remdesivir, which has demonstrated effectiveness in reducing mortality. We evaluated the economic impact realized by hospitals for patients hospitalized for SARS-CoV-2 infection and initiated on remdesivir therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis using data compiled in the Premier Healthcare Database from January 2023 to February 2024. Propensity score matching was used to compare remdesivir-treated (RDV) and untreated (No RDV) groups. The mortality rate, hazard ratios associated with remdesivir use, and hospitalization costs were assessed overall and among the elderly (age \u226565 years). We also conducted a cost-effectiveness analysis to assess the economic value of remdesivir treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 25,498 hospitalized patients, the mortality rate in the RDV group was lower than in the No RDV group (6.2% versus 8.1%), with a greater reduction in the elderly (6.9% versus 9.0%). Remdesivir significantly reduced mortality risk by approximately 25% overall and among the elderly. Each life saved was realized at a minimal increase in average hospitalization costs ($18,329 in the RDV group versus $14,845 in the No RDV group). Remdesivir was a cost-effective treatment option at a willingness-to-pay threshold of $25,000 overall and among the elderly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our evaluation provides contemporaneous evidence of benefits and costs associated with management of individuals hospitalized for SARS-CoV-2 infection. Initiation of remdesivir was associated with minimal incremental hospitalization costs for lives saved as compared to not initiating remdesivir. Hospital pharmacy leadership can utilize this real-world evidence to appropriately budget for remdesivir treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag038","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:26:45Z","timestamp":1770726405000},"page":"S2952-S2961","source":"Crossref","is-referenced-by-count":0,"title":["Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspective"],"prefix":"10.1093","volume":"83","author":[{"given":"Andre C","family":"Kalil","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center , Omaha, NE ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Yaghoubi","sequence":"additional","affiliation":[{"name":"Evidence and Access, Certara , Radnor, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neera","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananth","family":"Kadambi","sequence":"additional","affiliation":[{"name":"Evidence and Access, Certara , Radnor, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2865-9854","authenticated-orcid":false,"given":"Thomas","family":"Oppelt","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina G","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"10","key":"2026041222233303700_zxag038-B1","doi-asserted-by":"publisher","first-page":"ofad482","DOI":"10.1093\/ofid\/ofad482","article-title":"Remdesivir is associated with reduced mortality in COVID-19 patients requiring supplemental oxygen including invasive mechanical ventilation across SARS-CoV-2 variants","volume":"10","author":"Mozaffari","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2026041222233303700_zxag038-B2","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"suppl 4","key":"2026041222233303700_zxag038-B3","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1093\/cid\/ciae510","article-title":"Remdesivir-associated survival outcomes among immunocompromised patients hospitalized for COVID-19: real-world evidence from the omicron-dominant era","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026041222233303700_zxag038-B4"},{"issue":"7","key":"2026041222233303700_zxag038-B5","doi-asserted-by":"publisher","first-page":"e0254523","DOI":"10.1371\/journal.pone.0254523","article-title":"Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study","volume":"16","author":"Menges","year":"2021","journal-title":"PLoS One"},{"key":"2026041222233303700_zxag038-B6"},{"key":"2026041222233303700_zxag038-B7","author":"Truveta"},{"issue":"22","key":"2026041222233303700_zxag038-B8","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2024.7395","article-title":"Mortality in patients hospitalized for COVID-19 vs influenza in fall-winter 2023-2024","volume":"331","author":"Xie","year":"2024","journal-title":"JAMA"},{"issue":"suppl 4","key":"2026041222233303700_zxag038-B9","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1093\/cid\/ciae517","article-title":"Public health benefits of applying evidence-based best practices in managing patients hospitalized for COVID-19","volume":"79","author":"Kalil","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026041222233303700_zxag038-B10"},{"issue":"19","key":"2026041222233303700_zxag038-B11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10236","key":"2026041222233303700_zxag038-B12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/s0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"suppl 4","key":"2026041222233303700_zxag038-B13","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1093\/cid\/ciae515","article-title":"Remdesivir for patients hospitalized with COVID-19: evidence of effectiveness from cohort studies in the omicron era","volume":"79","author":"Kuritzkes","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2026041222233303700_zxag038-B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/cid\/ciaf111","article-title":"A systematic review and meta-analysis of the effectiveness of remdesivir to treat SARS-CoV-2 infection in hospitalized patients: have the guidelines evolved with the evidence? Clin Infect Dis","volume":"81","author":"Bartoletti","year":"2025"},{"key":"2026041222233303700_zxag038-B15","author":"National Institutes of Health"},{"key":"2026041222233303700_zxag038-B16"},{"key":"2026041222233303700_zxag038-B17","article-title":"Remdesivir and tixagevimab plus cilgavimab for treating COVID-19","volume":"8","author":"National Institute for Health and Care Excellence","year":"2024","journal-title":"Technology appraisal guidance. Published May"},{"issue":"5","key":"2026041222233303700_zxag038-B18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jval.2021.11.1378","article-title":"The cost-effectiveness of remdesivir for hospitalized patients with COVID-19","volume":"25","author":"Whittington","year":"2022","journal-title":"Value Health"},{"key":"2026041222233303700_zxag038-B19"},{"key":"2026041222233303700_zxag038-B20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2147\/CLEP.S335621","article-title":"Positive predictive value of COVID-19 ICD-10 diagnosis codes across calendar time and clinical setting","volume":"13","author":"Lynch","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"19","key":"2026041222233303700_zxag038-B21","first-page":"1","article-title":"United States Life Tables, 2019","volume":"70","author":"Arias","year":"2022","journal-title":"Natl Vital Stat Rep"},{"issue":"12","key":"2026041222233303700_zxag038-B22","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/MLR.0b013e31814848f1","article-title":"US norms for six generic health-related quality-of-life indexes from the National Health Measurement study","volume":"45","author":"Fryback","year":"2007","journal-title":"Med Care"},{"key":"2026041222233303700_zxag038-B23","author":"The American Journal of Managed Care, AMJC"},{"issue":"4","key":"2026041222233303700_zxag038-B24","doi-asserted-by":"publisher","first-page":"e0263548","DOI":"10.1371\/journal.pone.0263548","article-title":"Mortality rates among COVID-19 patients hospitalised during the first three waves of the epidemic in Milan, Italy: a prospective observational study","volume":"17","author":"Giacomelli","year":"2022","journal-title":"PLoS One"},{"issue":"37","key":"2026041222233303700_zxag038-B25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods \u2013 United States, April 2020-June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2026041222233303700_zxag038-B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jval.2021.12.015","article-title":"A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales","volume":"25","author":"Rafia","year":"2022","journal-title":"Value Health"},{"issue":"9979","key":"2026041222233303700_zxag038-B27","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/s0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"issue":"10339","key":"2026041222233303700_zxag038-B28","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/s0140-6736(22)00519-0","volume":"399","author":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2026041222233303700_zxag038-B29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s15010-022-01930-8","article-title":"Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review","volume":"51","author":"Murton","year":"2023","journal-title":"Infection"},{"issue":"6","key":"2026041222233303700_zxag038-B30","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/jcm12062371","article-title":"Retrospective analysis of the effectiveness of remdesivir in COVID-19 treatment during periods dominated by Delta and Omicron SARS-CoV-2 variants in clinical settings","volume":"12","author":"Dobrowolska","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"2026041222233303700_zxag038-B31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40801-024-00452-z","article-title":"Evaluating the effectiveness of prophylactic strategies for hemophilia a management: a real-world, longitudinal observational study","volume":"11","author":"Chiou","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"2026041222233303700_zxag038-B32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/medicina59010181","article-title":"A real-world cost-effectiveness analysis of rivaroxaban versus vitamin K antagonists for the treatment of symptomatic venous thromboembolism: lessons from the REMOTEV registry","volume":"59","author":"Kepka","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"2026041222233303700_zxag038-B33","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jval.2023.08.008","article-title":"Real-world cost-effectiveness of pulmonary vein isolation for atrial fibrillation: a target trial approach","volume":"26","author":"Serra-Burriel","year":"2023","journal-title":"Value Health"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag038\/66852878\/zxag038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_3\/S2952\/66852878\/zxag038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_3\/S2952\/66852878\/zxag038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:23:42Z","timestamp":1776047022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/Supplement_3\/S2952\/8472892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":33,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag038","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,1]]},"published":{"date-parts":[[2026,2,11]]}}}